Cystitis, Interstitial Clinical Trial
Official title:
Exercise and Meditation: A Pilot Study of Alternative Techniques in the Treatment of Chronic Pelvic Pain Related to Painful Bladder Syndrome (PBS)/Interstitial Cystitis (IC) PI: Dr. Christopher Payne
Verified date | March 2011 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Complementary and alternative medicine (CAM) is the term for medical products and/or practices that are not part of the current standard of care. Standard care is what medical doctors, doctors of osteopathy and allied health professionals, such as registered nurses and physical therapists, practice. Alternative medicine means treatments that you use instead of standard ones. Complementary medicine means nonstandard treatments that you use along with standard ones. The purpose of this study is to determine whether there is any improvement in symptoms reported by patients with chronic painful bladder syndrome when participating in alternative medical therapy/ exercise and meditative techniques. The specific alternative techniques participants will be randomized to in this trial include: Tai Chi instruction or walking exercise combined with sitting meditation.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2008 |
Est. primary completion date | December 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participant has signed and dated the appropriate Informed Consent document. 2. Participant is equal or > 18 years old 3. Participant has a clinical diagnosis of IC/PBS and or CP/CPPS in the opinion of the investigator 4. Participant with IC/PBS has reported a bladder pain or discomfort symptom score of 3 or greater on a 0-10 Likert scale over the previous four weeks. This bladder pain/discomfort criterion must be met at each of the two baseline screening visits as reported by the participant. 5. Participant with IC/PBS has reported a symptom score of abnormal urinary frequency of 3 or greater on 0-10 Likert scale over the previous four weeks. This frequency criterion must be met at least each of the two baseline screening visits. 6. Participant has had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months. 7. Participant has previously undergone at least one course of other form of standard therapy for his/her symptoms Exclusion Criteria:1. Participant can not stand in place for at least 15 minutes. Exclusion Criteria: 1. Participants have severe lower extremity disease that would prohibit participation in walking or Tai Chi movements. 2. Participant cannot hold urine for at least 30 minutes 3. Participant has relevant neurologic disorder that affects bladder and/or neuromuscular function in the opinion of the investigator. 4. Participant has active urethral or ureteral calculi, urethral diverticulum. 5. Participant has a history of pelvic radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ, prostate cancer, or urethral cancer. 6. Participant has/reports any severe debilitating or urgent concurrent medical condition. 7. Participant has a potentially significant pelvic pathology or abnormalities on examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass, etc. that could cause or contribute to the clinical symptoms or require treatment. |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University School of Medicine | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
Terminated |
NCT00380783 -
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT05260112 -
Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide
|
N/A | |
Completed |
NCT05752344 -
Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
|
||
Completed |
NCT01613586 -
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
|
Phase 2 | |
Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Completed |
NCT00248664 -
Events Preceding Interstitial Cystitis (EPIC)
|
N/A | |
Completed |
NCT00601484 -
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
|
Phase 2 | |
Completed |
NCT02214550 -
Chronic Pain Risk Associated With Menstrual Period Pain
|
Phase 4 | |
Completed |
NCT04275297 -
Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Terminated |
NCT00999518 -
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
|
Phase 2 | |
Completed |
NCT00675298 -
Linkage Analysis in Interstitial Cystitis
|
N/A | |
Terminated |
NCT02781103 -
Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain
|
N/A | |
Recruiting |
NCT01074567 -
DMSO Efficacy in IC/PBS Patients During and After Treatment
|
N/A | |
Completed |
NCT02497976 -
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
|
Phase 3 | |
Terminated |
NCT02787083 -
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
|
Phase 3 |